Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 103 Carcinoma, Renal Cell 70 Neoplasm Metastasis 48 Neoplasms 37 Neuroendocrine Tumors 33 Kidney Neoplasms 27 Recurrence 19 Tuberous Sclerosis 18 Carcinoma, Non-Small-Cell Lung 17 Prostatic Neoplasms 16 Triple Negative Breast Neoplasms 15 Lymphoma 15 Lymphoma, Mantle-Cell 14 Lymphoma, Large B-Cell, Diffuse 14 Head and Neck Neoplasms 14 Glioblastoma 14 Colorectal Neoplasms 13 Carcinoma, Hepatocellular 13 Stomach Neoplasms 12 Lung Neoplasms 12 Leukemia, Lymphocytic, Chronic, B-Cell 12 Hodgkin Disease 12 Brain Neoplasms 12 Sarcoma 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Pancreatic Neoplasms 11 Glioma 11 Waldenstrom Macroglobulinemia 10 Lymphoma, Follicular 10 Carcinoma, Neuroendocrine 10

Interventions

tanespimycin 2 pembrolizumab 2 parsaclisib 2 cemiplimab 2 Midazolam 2 MLN 8237 2 Injections 2 Capecitabine 2 zanidatamab 1 tislelizumab 1 spartalizumab 1 sitravatinib 1 repaglinide 1 pemigatinib 1 pamiparib 1 liposomal doxorubicin 1 lenvatinib 1 epothilone B 1 drospirenone 1 cabiralizumab 1 Temozolomide 1 Pemetrexed 1 Paclitaxel 1 Nivolumab 1 N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1 MLN8054 1 Ipilimumab 1 HMPL-013 1 Gemcitabine 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced Malignancies × Everolimus × Clear all

NCT01079702 2010-03-03

m-TOR

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Unknown

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡